UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2023
SALT LAKE CITY, UT, July 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Utah Medical Products, Inc. achieved second calendar...
Pharmaceutical
Medicure to Present Financial Results on July 31, 2023 Call at 8:30 AM ET for Quarter Ended June 30, 2023
WINNIPEG, MB / ACCESSWIRE / July 24, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused...
Apellis Pharmaceuticals to Host Conference Call on July 31, 2023, to Discuss Second Quarter 2023 Financial Results
WALTHAM, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement,...
Marius Pharmaceuticals Announces Launch of ReThink Testosterone, Disease-State Awareness Initiative for Patients
RALEIGH, N.C., July 24, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company specializing in therapies for hypogonadism or...
Curia expands biologics capabilities with access to Touchlight’s doggybone DNA
Curia collaborates with Touchlight to expand its mRNA manufacturing offering to enable access to enzymatic doggybone DNA (dbDNA™)ALBANY, N.Y. and...
BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population
Initial topline data from COVALENT-101 trial revealed 2 complete responses (CRs) out of 5 relapsed/refractory AML patients carrying menin-dependent mutations...
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor – The GRI Opportunity Spotlight Event
- Live moderated webcast with members of the GRI Bio management team on Thursday, July 27th at 1:00 PM ET...
Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors
SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of...
Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate
Dosing of patients completed at the end of FebruaryData Safety Monitoring Board conducted analysis of Day 29 data No major...
TOMI Announces Preliminary Second Quarter Revenue Growth of 90%
FREDERICK, Md., July 24, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in...
Assertio Holdings, Inc. to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023
LAKE FOREST, Ill., July 24, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty...
Panbela Opens Enrollment in UK and Germany for Aspire Trial in Pancreatic Cancer, All Countries/Regions in the Aspire Trial are Now Open and Actively Enrolling
Interim Data Analysis anticipated in Early 2024MINNEAPOLIS, July 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical...
Catalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023
The Company to Host a Conference Call and Webcast on August 10, 2023, at 8:30 AM ETCORAL GABLES, Fla., July...
AUROBAC THERAPEUTICS welcomes two new independent members to its Board: Manos Perros, as Chairman, and Marco Taglietti
These new appointments bring extensive US and international experience in company leadership and development of anti-infectives from R&D to commercialization.Lyon...
Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension
Keros Therapeutics announces U.S. Food and Drug Administration (“FDA”) has cleared its investigational new drug application to conduct a Phase...
Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors
– Ms. Tomasello created and led global commercial and medical affairs functions at Kite Pharma from pre-launch through its acquisition...
ZyVersa Therapeutics, Inc. Announces Pricing of $2.1 Million Public Offering
WESTON, Fla., July 24, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa” or “the Company”), a clinical...
Ocular Therapeutix™ To Report Second Quarter 2023 Financial Results
BEDFORD, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and...
PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301
The study’s primary endpoint was reached and demonstrated statistically significant and clinically meaningful resultsThese results pave the way for filing...
SomaLogic partners with Dante Genomics to enhance clinical and research adoption of proteomics in Europe
SomaLogic’s 7,000-plex SomaScan® Platform will be used in proteomics testing at scale in EuropeBOULDER, Colo. and L’AQUILA, Italy, July 24,...